Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 508

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 508
---
 52  
     (32)
  
    Accounts payable and accrued liabilities 
     (1,362) 
     2,695 
  
    Accounts payable and accrued liabilities – related parties 
     (10) 
     26 
  
    Deferred liabilities 
     28  
     (127)
  
    Accrued liability – long-term 
     -  
     (550)
  
    Operating lease liability 
     (25) 
     (4)
  
    Net cash used in operating activities 
     (33,361) 
     (11,980)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,789  
     775 
  
    Repayment of debt 
     (10,000) 
     (5,000)
  
    Net proceeds from the exercise of stock options 
     422  
     - 
  
    Net cash provided by (used in) financing activities 
     18,211  
     (4,225)

    Impact on cash from foreign currency translation 
     224  
     (100)

    NET DECREASE IN CASH 
     (14,926) 
     (16,305)
  
    CASH AT BEGINNING OF YEAR 
     35,848  
     52,153 
  
    CASH AT END OF YEAR 
    $20,922  
    $35,848 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $1,690  
    $1,778 

See accompanying notes to these consolidated financial
statements.

F-6

INMUNE BIO INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND BASIS
OF PRESENTATION

Organization and Business Overview

INmune Bio Inc. (the “Company” or
“INmune Bio”) was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical
company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning
normally and contributing to the patient’s disease. INmune Bio has three product